|Videos|January 4, 2017

How Can Pharmacists and Physicians Work Together to Optimize Patient Care?

Kerry LaPlante, professor of Pharmacy, University of Rhode Island, adjunct professor of Medicine, Brown University, director of the Rhode Island Infectious Diseases Research Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center, discusses how pharmacists and physicians can work together in the hospital setting to optimize patient care.

Kerry LaPlante, professor of Pharmacy, University of Rhode Island, adjunct professor of Medicine, Brown University, director of the Rhode Island Infectious Diseases Research Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center, discusses how pharmacists and physicians can work together in the hospital setting to optimize patient care.

Interview Transcript (slightly modified for readability)

“As we know, antibiotics are a scarce resource for us right now, and drug resistance is an important public health concern. I think we’re at [a] time where we need to work together with physicians, pharmacists, microbiologists, and nurses as an interdisciplinary team and do what we can for the patient. These relationships are all based on trust, they’re based on partnerships, and everyone has a unique but important role in treating the patient to get the best outcomes and to keep our patients safe. [An] example [is] the role of the pharmacist, and the evolving role of the pharmacist. Really, when it comes to selecting the right drug at the right dose for the right duration, in empiric therapy, what we can do is work together, pharmacists and physicians, to create pathways and guidance documents for the rest of the treating team, for the patients.

When it comes to selecting the right dose, what pharmacists have good expertise in is making sure that the patient, if they have renal failure, if they have liver failure, if they have other drug-drug interactions, or other things going on, can [get an] optimized drug therapy [regimen]. [For] duration, IDSA guidance give us recommendations on how long to treat patients, and this is something that, with policies and procedures in place at a hospital, pharmacists can help work with physicians and enforce.

What we do at our clinical practice is, for example, every day the pharmacist will pull all antibiotic use and all blood cultures from the microbiology lab, [and] we review that, we look for appropriateness, correct drug, dose, and duration. When there are simple changes, like IV to oral switch, when they’re deescalating therapy because the culture is back, when there’s no growth and we have to stop the therapy, that’s when the pharmacist will come in and have those conversations with the team. When there [are] more challenging cases, that is when we’ll bring in our infectious diseases physician who will call surgery or urology and get a little more understanding on the [pathophysiology] or what specifically is going on with that patient.

I think we play a very important role; it’s certainly a team approach. I heard a colleague say ‘wouldn’t we want a two-parent household? Wouldn’t we want a mom and a dad? Wouldn’t we want an ID physician and an ID pharmacist working together to do the best we can for our patients?’ I think that pharmacists have an important role, and ID physicians, nurses, microbiologists, we all need to work together.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.